[
    {
        "header": "Abstract",
        "images": []
    },
    {
        "header": "1Introduction",
        "images": []
    },
    {
        "header": "2Related work",
        "images": []
    },
    {
        "header": "3Method",
        "images": [
            {
                "img": "https://arxiv.org/html/2511.15906/x1.png",
                "caption": "Figure 1:Neural field architectures. (a) Architecture used inkirchmeyer2024funcmolwhere a global embedding is used as input to the neural field decoder. (b) Our proposed neural field architecture, where embeddings are spatially arranged into a feature map grid. The latter allows us to better capture local signal information from input space and is compatible with expressive architectures for denoising.",
                "position": 223
            },
            {
                "img": "https://arxiv.org/html/2511.15906/x2.png",
                "caption": "Figure 2:Conditional denoiser training overview. We voxelize separately the bindervvand the targetvtarv_{\\rm tar}of a given complex and encode them intoz,ztarz,{z^{\\rm tar}}using encodersEψ,Eψ′E_{\\psi},E_{\\psi^{\\prime}}, respectively. We train a denoiserz^θ​(y∣ztar,σ,c)\\hat{z}_{\\theta}(y\\mid{z^{\\rm tar}},\\sigma,c)to remove the noise fromyyconditioned onztarz_{\\rm tar}, the noise levelσ\\sigmaand the one-hot modality classcc(e.g. a cyclic peptide). The denoised latent representation is fed into a neural field decoderDϕD_{\\phi}; this gives a reconstructed fieldv^\\hat{v}.v^\\hat{v}undergoes some additional postprocessing to recover the bonds and residue identities (if applicable); seeSection˜3.3.",
                "position": 275
            }
        ]
    },
    {
        "header": "4Experiments",
        "images": [
            {
                "img": "https://arxiv.org/html/2511.15906/x3.png",
                "caption": "Figure 3:Examples of generated molecules given a target structure for different modalities: (top) small molecules against2rma, (middle) macrocyclic peptides against5oocand (bottom) CDR H3 loop against5tlk. The seed binders are shown on the right.",
                "position": 364
            },
            {
                "img": "https://arxiv.org/html/2511.15906/x4.png",
                "caption": "Figure 4:CDR H3 length (left) and atom count (right) histogram on thede-novo4cnitarget. Red is the seed H3’s reference numbers.",
                "position": 1019
            },
            {
                "img": "https://arxiv.org/html/2511.15906/x4.png",
                "caption": "",
                "position": 1022
            },
            {
                "img": "https://arxiv.org/html/2511.15906/x5.png",
                "caption": "",
                "position": 1026
            },
            {
                "img": "https://arxiv.org/html/2511.15906/x6.png",
                "caption": "Figure 5:Per-residue energy scores at the same position were calculated using Rosetta’s residue energy breakdown for a seed and two samples. We analyzed: (a) the seed’s serine, (b) 3-hydroxycyclopentyl-alanine (C1O) from sample 11 (Section˜E.1Figure˜12), (c) tyrosine from sample 35.",
                "position": 1151
            }
        ]
    },
    {
        "header": "5Conclusion",
        "images": []
    },
    {
        "header": "Appendix ABroader impacts",
        "images": []
    },
    {
        "header": "Appendix BModel details",
        "images": []
    },
    {
        "header": "Appendix CCDR redesign",
        "images": [
            {
                "img": "https://arxiv.org/html/2511.15906/x7.png",
                "caption": "Figure 6:All generated CDR H3 designs on rigid epitope: AAR (left) and RMSD (right) histogram.",
                "position": 1728
            },
            {
                "img": "https://arxiv.org/html/2511.15906/x8.png",
                "caption": "",
                "position": 1731
            },
            {
                "img": "https://arxiv.org/html/2511.15906/figures/in-vitro_T1.png",
                "caption": "Figure 7:In vitro validation of FuncBind’s designs against a rigid epitope; expression (left), binding affinity (center), binding rate (right). Expression rate is 93.68%.",
                "position": 1769
            },
            {
                "img": "https://arxiv.org/html/2511.15906/x9.png",
                "caption": "Figure 8:All generated CDR H3 designs against a flexible epitope; target: AAR (top left) and RMSD (top right) histogram. Bottom: Logo of generated designs.",
                "position": 1780
            },
            {
                "img": "https://arxiv.org/html/2511.15906/x10.png",
                "caption": "",
                "position": 1785
            },
            {
                "img": "https://arxiv.org/html/2511.15906/figures/in-vitro_T2.png",
                "caption": "Figure 9:In vitro validation of FuncBind’s designs against a flexible epitope; expression (left), binding affinity (center), binding rate (right). Expression rate is 100%.",
                "position": 1828
            }
        ]
    },
    {
        "header": "Appendix DIdentifying non canonical amino acids",
        "images": [
            {
                "img": "https://arxiv.org/html/2511.15906/x11.png",
                "caption": "Figure 10:Results of sampling in pocket relaxed around MCP seed (grey) are in (a) blue in 4gw5 mutant 104 pocket, (b) purple for 1vwe mutant 90 pocket, and (c) 1wb0 mutant 389 pocket",
                "position": 1885
            },
            {
                "img": "https://arxiv.org/html/2511.15906/x12.png",
                "caption": "Figure 11:Proportion of amino acid types classified as L-canonical, D-canonical, N-methylated, other known non-canonical amino acids (as annotated in our library), and unknown non-canonical amino acids in the sampled set.",
                "position": 1931
            },
            {
                "img": "https://arxiv.org/html/2511.15906/x13.png",
                "caption": "Figure 12:Examples of unknown or novel NCAAs that appeared in the sampled set but were not present in the initial test set library. Novel NCAAs are labeled with a formal name and an assigned 3-letter AA code.",
                "position": 1934
            },
            {
                "img": "https://arxiv.org/html/2511.15906/x14.png",
                "caption": "Figure 13:(a) Count of MCPs with each amino acid length in the source MCP-protein dataset. (b) Percentage of the number of mutations in the curated MCP-protein bound dataset.",
                "position": 1947
            }
        ]
    },
    {
        "header": "Appendix EMacro cyclic peptides",
        "images": []
    }
]